The global respiratory syncytial virus market is expected to register a CAGR of 14.9% growth and revenue is expected to increase from US$ 1,823.3 Million in 2021 to reach 4,202.6 Million by 2030.
Get a Free Sample Copy of this Report@ https://www.astuteanalytica.com/request-sample/respiratory-syncytial-virus-market
Respiratory Syncytial Virus (RSV) is the major reason behind the number of respiratory disorders, including bronchiolitis, bronchitis, or pneumonia. RSV symptoms are pretty much similar to a typical cold in healthy persons. However, it can progress to a severe condition in individuals with a compromised immune system or the elderly. Moreover, cough, sputum production, wheezing, and fever were some of the most prevalent clinical symptoms.
Factor such as increased disease prevalence and the advent of targeted therapies drives the growth in the global respiratory syncytial virus market over the forecast period. The most common targeted therapy is the use of antiviral drugs specifically to inhibit one or more steps of virus replication. Moreover, rising government funding for treatment and proactive government initiatives creates a lucrative growth opportunity in the market. However, the high cost of technology and inaccessibility of diagnostic facilities inhibits the market growth. The high cost is associated due to the application of advanced technology in the medical field and the complexity of developing and manufacturing biological products.
On the basis of drug type, the synagis segment held the largest share in the respiratory syncytial virus market in 2021 as its FDA-approved prescription contains virus-fighting antibodies and aids in the prevention of serious respiratory tract infections. Whereas virazole is expected to grow at the highest CAGR during the forecast period due to its characteristic of having a broad spectrum of antiviral activity in vitro.
Moreover, based on dosage form, the injectable segment is estimated to hold the largest market share over the forecast period. Whereas the oral segment is anticipated to project the highest CAGR owing to its beneficial features of safety, good patient compliance, ease of ingestion, and pain avoidance.
Furthermore, by treatment type, the immune prophylaxis segment dominated the respiratory syncytial virus market in 2021. Whereas the antiviral medication segment is anticipated to grow at the highest CAGR over the forecast period as it decreases the chances of RSV hospitalization in premature babies. Also, many known pharmaceutical companies are involved in the development of drugs against RSV infection.
In addition, based on the distribution channel, the hospital segment dominated the market in 2021 due to the increased number of hospitalizations. Whereas the clinic segment is projected to grow at the highest CAGR during the forecast period. Due to the availability of drugs, online patient monitoring, and low availability of space in hospitals, there was significant growth in the clinics. Also, due to the pandemic situation, people avoid visiting hospitals.
By region, North America holds the largest market share in 2021 owing to high prevalence of RSV infection in the region. Whereas Asia Pacific is anticipated to project the highest CAGR over the forecast period. Countries like Japan and Australia have developed healthcare infrastructure and have a higher penetration of respiratory syncytial virus medicines.
Scope of Treatment
Vaccine- Currently, the focus of treatment is on vaccines intended for infants and toddlers (aged 28 days to 23 months), and pregnant women, with the intent to prevent RSV in their infants and older adults.
Monoclonal Antibodies- The focus of treatment is to use monoclonal antibodies that exert virus neutralization activity for preexposure prophylaxis of RSV disease in neonates (age 0-27 days), infants, and toddlers.
Antiviral Agents- The focus is on evaluating direct-acting antiviral agents (DAAs) for the treatment of RSV disease in infants and toddlers and in elderly people, with or without co-morbidities or immunodeficiencies predisposing them to RSV disease.
Company Profile
- AbbVie, Inc. operates across several key therapeutic areas such as immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. They combine advanced science, expertise, and passion in order to solve the world’s most serious health issues and have a remarkable impact on people’s lives. Moreover, immunology holds the highest share in terms of business revenue segmentation.
- Atea Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company focuses on the discovery of oral direct-acting antiviral therapies and serves all types of patients, healthcare professionals, pharmaceutical, and biotechnology industries worldwide. It is a clinical-stage biopharmaceutical company working to address unmet medical needs through novel antiviral treatments.
- Gilead Sciences, Inc., is an American biopharmaceutical company that mainly focuses on researching and developing antiviral drugs which are used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. It is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. Its product comprises HIV and influenza diseases.
Competitive Insight
The global Respiratory Syncytial Virus Market is highly competitive in nature. Some of the key players operating in the market include AstraZeneca, AbbVie, Inc., Bausch Health Companies, Inc., Pfizer, Inc., SOBI, GlaxoSmithKline, GlaxoSmithKline, Johnson & Johnson, and Pfizer among others.
Segmentation Overview
The industry trends in the Global Respiratory Syncytial Virus market are sub-divided into different categories in order to get a holistic view of the global marketplace. Following are the different segments of the Global Respiratory Syncytial Virus Market:
Drug Type
- Ribavirin
- Synagis
- Virazole
- Palivizumab
- Riba Tab
- Others
Dosage Form
- Oral
- Injectable
- Inhaler
- Others
Treatment Type
- Immune prophylaxis
- Supportive care
- Antiviral Medications
Distribution Channel
- Hospital pharmacies
- Drug Stores
- Retail pharmacies
- Clinics
By Region
- North America
- The U.S.
- Canada
- Mexico
- Europe
- The UK
- Germany
- France
- Italy
- Spain
- Poland
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia & New Zealand
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of MEA
- South America
- Argentina
- Brazil
- Rest of South America
Access Full Report@ https://www.astuteanalytica.com/request-sample/respiratory-syncytial-virus-market
About Astute Analytica
Astute Analytica is a global analytics and advisory company which has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.
Contact us:
Aamir Beg
BSI Business Park, H-15,Sector-63, Noida- 201301- India
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
Email: sales@astuteanalytica.com
Website: www.astuteanalytica.com
Follow US: LinkedIn | Twitter